vs
MAXCYTE, INC.（MXCT）与NATIONAL RESEARCH CORP（NRC）财务数据对比。点击上方公司名可切换其他公司
NATIONAL RESEARCH CORP的季度营收约是MAXCYTE, INC.的7.4倍（$35.2M vs $4.8M）。NATIONAL RESEARCH CORP净利率更高（5.1% vs -200.5%，领先205.6%）。NATIONAL RESEARCH CORP同比增速更快（-4.6% vs -20.9%）。NATIONAL RESEARCH CORP自由现金流更多（$6.1M vs $-2.9M）。过去两年NATIONAL RESEARCH CORP的营收复合增速更高（-0.2% vs -7.4%）
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
MXCT vs NRC — 直观对比
营收规模更大
NRC
是对方的7.4倍
$4.8M
营收增速更快
NRC
高出16.3%
-20.9%
净利率更高
NRC
高出205.6%
-200.5%
自由现金流更多
NRC
多$9.0M
$-2.9M
两年增速更快
NRC
近两年复合增速
-7.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $35.2M |
| 净利润 | $-9.6M | $1.8M |
| 毛利率 | — | — |
| 营业利润率 | -234.5% | 13.3% |
| 净利率 | -200.5% | 5.1% |
| 营收同比 | -20.9% | -4.6% |
| 净利润同比 | 9.4% | -72.6% |
| 每股收益（稀释后） | — | $49.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MXCTNRC
| Q4 25 | $4.8M | $35.2M | ||
| Q3 25 | $4.6M | $34.6M | ||
| Q2 25 | $5.8M | $34.0M | ||
| Q1 25 | $5.7M | $33.6M | ||
| Q4 24 | $6.1M | $36.9M | ||
| Q3 24 | $5.6M | $35.8M | ||
| Q2 24 | $5.0M | $35.0M | ||
| Q1 24 | $5.6M | $35.3M |
净利润MXCTNRC
| Q4 25 | $-9.6M | $1.8M | ||
| Q3 25 | $-12.4M | $4.1M | ||
| Q2 25 | $-12.4M | $-106.0K | ||
| Q1 25 | $-10.3M | $5.8M | ||
| Q4 24 | $-10.6M | $6.6M | ||
| Q3 24 | $-11.6M | $5.7M | ||
| Q2 24 | $-9.4M | $6.2M | ||
| Q1 24 | $-9.5M | $6.4M |
营业利润率MXCTNRC
| Q4 25 | -234.5% | 13.3% | ||
| Q3 25 | -307.4% | 22.4% | ||
| Q2 25 | -244.3% | 4.7% | ||
| Q1 25 | -214.1% | 25.6% | ||
| Q4 24 | -213.1% | 26.0% | ||
| Q3 24 | -250.4% | 22.3% | ||
| Q2 24 | -241.0% | 25.3% | ||
| Q1 24 | -219.8% | 24.8% |
净利率MXCTNRC
| Q4 25 | -200.5% | 5.1% | ||
| Q3 25 | -269.7% | 11.9% | ||
| Q2 25 | -212.2% | -0.3% | ||
| Q1 25 | -178.7% | 17.2% | ||
| Q4 24 | -175.0% | 17.8% | ||
| Q3 24 | -205.9% | 15.9% | ||
| Q2 24 | -188.8% | 17.6% | ||
| Q1 24 | -170.6% | 18.0% |
每股收益（稀释后）MXCTNRC
| Q4 25 | — | $49.58 | ||
| Q3 25 | $-0.12 | $0.18 | ||
| Q2 25 | $-0.12 | $-0.01 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | $-0.11 | $0.24 | ||
| Q2 24 | $-0.09 | $0.26 | ||
| Q1 24 | — | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.0M | $4.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $171.5M | $14.0M |
| 总资产 | $202.5M | $134.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MXCTNRC
| Q4 25 | $103.0M | $4.1M | ||
| Q3 25 | $105.7M | $2.2M | ||
| Q2 25 | $126.6M | $5.3M | ||
| Q1 25 | $138.3M | $2.5M | ||
| Q4 24 | $154.5M | $4.2M | ||
| Q3 24 | $153.8M | $3.5M | ||
| Q2 24 | $157.3M | $485.0K | ||
| Q1 24 | $157.5M | $1.7M |
总债务MXCTNRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $48.7M | ||
| Q2 24 | — | $33.3M | ||
| Q1 24 | — | $35.2M |
股东权益MXCTNRC
| Q4 25 | $171.5M | $14.0M | ||
| Q3 25 | $180.3M | $14.3M | ||
| Q2 25 | $190.7M | $21.3M | ||
| Q1 25 | $199.4M | $29.7M | ||
| Q4 24 | $206.3M | $31.3M | ||
| Q3 24 | $213.3M | $34.6M | ||
| Q2 24 | $221.3M | $40.2M | ||
| Q1 24 | $226.4M | $36.9M |
总资产MXCTNRC
| Q4 25 | $202.5M | $134.9M | ||
| Q3 25 | $213.5M | $135.7M | ||
| Q2 25 | $219.8M | $141.4M | ||
| Q1 25 | $230.0M | $135.2M | ||
| Q4 24 | $239.5M | $132.5M | ||
| Q3 24 | $248.6M | $131.8M | ||
| Q2 24 | $251.5M | $119.1M | ||
| Q1 24 | $257.9M | $120.9M |
负债/权益比MXCTNRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | 0.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.7M | $7.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $6.1M |
| 自由现金流率自由现金流/营收 | -61.0% | 17.2% |
| 资本支出强度资本支出/营收 | 4.8% | 3.2% |
| 现金转化率经营现金流/净利润 | — | 3.99× |
| 过去12个月自由现金流最近4个季度 | $-36.2M | $15.7M |
8季度趋势，按日历期对齐
经营现金流MXCTNRC
| Q4 25 | $-2.7M | $7.2M | ||
| Q3 25 | $-7.5M | $13.8M | ||
| Q2 25 | $-9.9M | $-1.1M | ||
| Q1 25 | $-14.4M | $6.6M | ||
| Q4 24 | $-7.8M | $6.4M | ||
| Q3 24 | $-4.4M | $9.4M | ||
| Q2 24 | $-4.8M | $6.8M | ||
| Q1 24 | $-10.6M | $12.0M |
自由现金流MXCTNRC
| Q4 25 | $-2.9M | $6.1M | ||
| Q3 25 | $-7.8M | $10.2M | ||
| Q2 25 | $-10.4M | $-4.1M | ||
| Q1 25 | $-15.1M | $3.7M | ||
| Q4 24 | $-8.0M | $1.9M | ||
| Q3 24 | $-4.8M | $7.8M | ||
| Q2 24 | $-5.1M | $1.5M | ||
| Q1 24 | $-11.4M | $7.9M |
自由现金流率MXCTNRC
| Q4 25 | -61.0% | 17.2% | ||
| Q3 25 | -168.5% | 29.4% | ||
| Q2 25 | -179.2% | -12.2% | ||
| Q1 25 | -262.3% | 10.9% | ||
| Q4 24 | -131.6% | 5.2% | ||
| Q3 24 | -85.5% | 21.8% | ||
| Q2 24 | -103.3% | 4.3% | ||
| Q1 24 | -203.6% | 22.4% |
资本支出强度MXCTNRC
| Q4 25 | 4.8% | 3.2% | ||
| Q3 25 | 6.5% | 10.4% | ||
| Q2 25 | 10.0% | 8.8% | ||
| Q1 25 | 11.4% | 8.9% | ||
| Q4 24 | 2.4% | 12.0% | ||
| Q3 24 | 7.2% | 4.5% | ||
| Q2 24 | 5.9% | 15.0% | ||
| Q1 24 | 14.4% | 11.7% |
现金转化率MXCTNRC
| Q4 25 | — | 3.99× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
